Claims for Patent: 10,792,267

Summary for Patent: 10,792,267

Title:	Methods of treating mixed dyslipidemia
Abstract:	The present disclosure relates to, inter alia, methods of treating cardiovascular-related disease.
Inventor(s):	Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT), Manku; Mehar (Birmingham, GB)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	16/389,317
Patent Claims:	1. A method of treating or preventing a cardiovascular disease in a subject on statin therapy having type 2 diabetes, the method comprising administering to the subject a pharmaceutical composition comprising about 4 g of eicosapentaenoic acid ethyl ester per day, wherein the cardiovascular disease is myocardial infarction, stroke, or both. 2. The method of claim 1, wherein the statin therapy is stable statin therapy. 3. The method of claim 2, wherein the statin is selected from lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, fluvastatin, atorvastatin and simvastatin. 4. The method of claim 1, wherein the subject does not exhibit an increase in low density lipoprotein-C (LDL-C) levels after administration of the pharmaceutical composition as compared to baseline or placebo control. 5. The method of claim 1, wherein the subject has fasting baseline triglyceride levels between about 150 mg/dl to about 500 mg/dl. 6. The method of claim 1, wherein the subject exhibits a reduction in triglycerides levels by at least 30% after administration of the pharmaceutical composition. 7. The method of claim 1, wherein the subject exhibits a reduction in triglycerides levels by at least 40% after administration of the pharmaceutical composition. 8. The method of claim 1, wherein the subject exhibits a reduction in triglycerides levels by at least 50% after administration of the pharmaceutical composition. 9. The method of claim 1, wherein the 4 g of eicosapentaenoic acid ethyl ester is administered to the subject in 4 capsules. 10. The method of claim 9, wherein the capsules each comprises about 1 g of eicosapentaenoic acid ethyl ester. 11. The method of claim 1, wherein the pharmaceutical composition is administered to the subject in 1 to 4 dosage units per day. 12. The method of claim 1, wherein the pharmaceutical composition comprises at least about 90%, by weight of all fatty acids present, eicosapentaenoic acid ethyl ester. 13. The method of claim 1, wherein the subject has atherosclerosis.